Q2 2026 Nuvation Bio Inc. Earnings Call Transcript
Key Points
- IBTROZI net revenue grew 25% quarter-over-quarter to $23.2 million, with 85% of new patient starts in the first-line setting, indicating strong commercial execution.
- IBTROZI is now the market leader in ROS1-positive lung cancer for both first-line and overall new patient starts, with first-line starts growing 30% quarter-over-quarter.
- IBTROZI's clinical profile is differentiated, with a 90% ORR and 50-month median DOR in TKI-naive patients, and it is the only brain-penetrant ROS1 TKI without CNS warnings, supporting long-term patient adherence.
- Safusidenib's updated Phase 2 data show a 52% ORR and 79% 36-month PFS rate in low-grade glioma, which compares favorably to vorasidenib's 21% ORR and 52% 36-month PFS, reinforcing its potential.
- The company completed an oversubscribed convertible debt offering, raising $279.1 million net, which strengthens the balance sheet and extends cash runway to profitability and safusidenib launch.
- The ROS1 market is expanding, with a 20% increase in first-line TKI use since IBTROZI's launch, and the company is actively working to increase testing rates and shift patients from chemo/IO to targeted therapy.
- New patient starts declined to approximately 160 in Q2, as the TKI-pretreated patient pool has been largely captured, leading to a slowdown in later-line starts.
- The company faces competition from a newly approved ROS1 TKI (Zydelig) with a higher price, though its label includes CNS warnings and pancreatic toxicity, which may create market noise.
- Safusidenib's Phase 3 studies (SIGMA and G307) are not expected to read out until 2029, leaving a long timeline for potential regulatory approval in the low-grade glioma setting.
- The company's SG&A expenses increased to $42.6 million in Q2, reflecting high commercialization costs, and total operating expenses remain elevated at $73.3 million.
- The company's reliance on first-line patient growth is subject to market dynamics, including the need to convert patients from chemo/IO, which is a slow process despite NCCN guideline changes.
- The convertible debt offering, while beneficial, introduces potential dilution, and the company's cash position of $661 million may not be sufficient to fund all pipeline programs without additional financing.
Welcome to Nuvation Bio's second-quarter 2026 financial results and business update call. Today's call is being recorded, and a replay will be available on the company's website. (Operator Instructions)
Now I'd like to turn the call over to JR DeVita, Vice President of Corporate Development and Investor Relations at Nuvation Bio. Please go ahead.
Thank you. Good morning, everyone.
Earlier today, we issued a press release summarizing our financial results for the quarter ending June 30, 2026, and provided a business update. The press release is available on the investors section of our website at nuvationbio.com.
Today's call includes forward-looking statements, including statements about the therapeutic and commercial potential of IBTROZI and safusidenib, our development plans for safusidenib and our Drug-Drug Conjugate platform, along with our plans for future updates from these programs, the components of our anticipated product revenue,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
